Advertisement

Aktueller Stand der Gentherapie

  • Sigrid Nikol
Part of the Handbuch der Molekularen Medizin book series (HDBMOLEK, volume 7)

Zusammenfassung

Molekularbiologische Methoden, einschließlich der Gentherapie, sind in den letzten Jahren zunehmend ins Rampenlicht gerückt. Nach experimentellen Erfolgen und einer dementsprechend hohen Erwartungshaltung insbesondere bei der Therapie von Patienten mit hohem Leidensdruck, bei denen konventionelle Therapien bisher versagten, erfolgte bereits nach wenigen Jahren der Übergang in die klinische Testung. Nach der 1. therapeutischen Anwendung 1990 hat sich das große Potential der Gentherapie bestßtigt, wenn auch der Weg zur routinemßßigen Anwendung lßnger als erwartet ist.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aebischer P., Schluep M., Deglon N. et al. (1996) Erratum: Intrathecal delivery of CNTF using encapsulated genetieally modified xenogeneic cells in amyotrophie lateral sderosis patients. (Nat Med (1996) 2:696-699). Nat Med 2:1041CrossRefGoogle Scholar
  2. Albelda S.M. (1997) Gene therapy for lung cancer and mesothelioma. Chest [Suppl6] 111):144S–149SPubMedCrossRefGoogle Scholar
  3. Anderson R.J., Galatowiez G., Macdonald I.D., Lowdell M.W., Corbett T.J., Prentice H.G. (1997) Detection of adeno associated virus type 2 in sorted human bone marrow progenitor cells. Exp Hematol 25:256–262PubMedGoogle Scholar
  4. Barinaga M. (1993) Ribozymes: killing the messenger. Science 262:1512–1514PubMedCrossRefGoogle Scholar
  5. Barnes M.N., Deshane J.S., Rosenfeld M., Siegal B.G., Curiel D.T., Alvarez R.D. (1997) Gene therapy and ovarian cancer: a review. Obstet Gynecol 89:145–155PubMedCrossRefGoogle Scholar
  6. Bauer K.A. (1994) Hypercoagulability-A new cofactor in the protein C antieoagulant pathway. N Engl J Med 330:566–567PubMedCrossRefGoogle Scholar
  7. Baumgartner I., Pieczek A., Manor O. et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97:1114–1123PubMedCrossRefGoogle Scholar
  8. Belli F., Arienti F., Sulesuso J. et al. (1997) Active immunization of metastatic melanoma patients with interleukin 2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 44:197–203PubMedCrossRefGoogle Scholar
  9. Bellon G., Michelcalemard L., Thouvenot D. et al. (1997) Aerosol administration of a recombinant adenovirus expressing CFTR to cystic fibrosis patients: a phase I clinical trial. Hum Gene Ther 8:15–25PubMedCrossRefGoogle Scholar
  10. Blaese R.M., Anderson W.F., Culver K.W., Rosenberg S.A. (1990) The ADA human gene therapy dinieal protocol. Hum Gene Ther 1:327–362CrossRefGoogle Scholar
  11. Blaese R.M., Culver K.W., Miller A.D. et al. (1995) T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270:475–480PubMedCrossRefGoogle Scholar
  12. Bonini C., Ferrari G., Verzeletti S. et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719–1724PubMedCrossRefGoogle Scholar
  13. Bordignon C., Bonini C., Verzeletti S. et al. (1995a) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneie bone marrow transplantation. Hum Gene Ther 6:813–819PubMedCrossRefGoogle Scholar
  14. Bordignon C., Notarangelo L.D., Nobili N. et al. (1995b) Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270:470–475PubMedCrossRefGoogle Scholar
  15. Boucher R.C., Knowles M.R., Johnson L.G. et al. (1994) Gene therapy for cystic fibrosis using E1-deleted adenovirus: a phase I trial in the nasal cavity. The University of North Carolina at Chapel HilI. Hum Gene Ther 5:615–639PubMedCrossRefGoogle Scholar
  16. Buchschacher G.J., Panganiban A.T. (1992) Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol 66:2731–2739PubMedGoogle Scholar
  17. Bukrinsky M.I., Haggerty S., Dempsey M.P. et al. (1993) A nudear localization signal within HI-1 matrix protein that governs infection of non-dividing cells. Nature 365:666–669PubMedCrossRefGoogle Scholar
  18. Bums J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90:8033–8037Google Scholar
  19. Burrows F.J., Thorpe P.E. (1994) Vascular targeting-a new approach to the therapy of solid tumors. Pharmacol Ther 64:155–174PubMedCrossRefGoogle Scholar
  20. Burt K., Chema D., Timmons T. (1997) Tracing the dissemination of adenoviral vectors in patient body fluids (abstract). J Mol Med [Suppl 5] 75:B28(86)Google Scholar
  21. Calarota S., Bratt G., Nordlund S. et al. (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320–1325PubMedCrossRefGoogle Scholar
  22. Caplen N.J., Alton E.W., Middleton P.G. et al (1995) Liposomemediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1:39–46PubMedCrossRefGoogle Scholar
  23. Chan P.J., Kalugdan T., Su B.C. et al. (1995) Sperm as a noninvasive gene delivery system for preimplantation embryos. Fertil Steril 63: 1121–1124PubMedGoogle Scholar
  24. Chang M.W., Barr E., Min-Min-Lu, Barton K., Leiden J.M. (1995a) Adenovirus-mediated over-expression of the cyclin/cydin-dependent kinase inhibitor, p21 inhibits smooth musde cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 96:2260–2268PubMedCrossRefGoogle Scholar
  25. Chang M.W., Barr E., Seltzer J. et al. (1995b) Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of retinoblastoma gene product. Science 267:518–522PubMedCrossRefGoogle Scholar
  26. Chonn A., Cullis P.R. (1995) Recent advances in liposomal drug-delivery systems. Curr Opin Biotechnol 6:698–708PubMedCrossRefGoogle Scholar
  27. Conry R.M., LoBuglio A.F., Curiel D.T. (1996) Polynudeotidemediated immunization therapy of cancer. Semin Oncol 23:135–147PubMedGoogle Scholar
  28. Cornetta K., Srour E.F., Moore A. et al. (1996) Retroviral gene transfer in autologous bone marrow transplantation for adult acute leukemia. Hum Gene Ther 7:1323–1329PubMedCrossRefGoogle Scholar
  29. Crystal R.G. (1995) Transfer of genes to humans: early lessons and obstades to success. Science 270:404–410PubMedCrossRefGoogle Scholar
  30. Crystal R.G., McElvaney N.G., Rosenfeld M.A. et al. (1994) Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8:42–51PubMedCrossRefGoogle Scholar
  31. Crystal R.G., Jaffe A., Brody S. et al. (1995) A phase 1 study, in cystic fibrosis patients, of the safety, toxicity, and biological efficacy of a single administration of a replication deficient, recombinant adenovirus carrying the cDNA of the normal cystic fibrosis trans membrane conductance regulator gene in the lung. Hum Gene Ther 6:643–666PubMedCrossRefGoogle Scholar
  32. Culver K.W., Blaese R.M. (1994) Gene therapy for cancer. Trends Genet 10:174–178PubMedCrossRefGoogle Scholar
  33. Culver K.W., Osborne W.R., Miller A.D. et al. (1991 a) Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc 23: 170–171PubMedGoogle Scholar
  34. Culver K.W., Anderson W.F., Blaese R.M. (1991 b) Lymphocyte gene therapy. Hum Gene Ther 2:107–109PubMedCrossRefGoogle Scholar
  35. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584PubMedCrossRefGoogle Scholar
  36. Davidson A., Morey S., Musk A.W. et al. (1997) Gene therapy or therapy by intratumoral cytokines by infusion in mesothelioma patients. Lung Cancer [Suppl 2] 18:94CrossRefGoogle Scholar
  37. Deisseroth A.B., Kavanagh J., Charnplin R. (1994) Clinical protocol: use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 5:1507–1522PubMedCrossRefGoogle Scholar
  38. Deshane J., Siegal G.P., Wang M.H. et al. (1997) Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti Erbb 2 intracellular single chain antibody for ovarian cancer gene therapy. Gynecol Oncol 64:378–385PubMedCrossRefGoogle Scholar
  39. Diehek D.A., Neville R.F., Zwiebel J.A., Freeman S.M., Leon M.B., Anderson W.F. (1989) Seeding of intravascular stents with genetieally engineered endothelial cells. Circulation 80:1347–1353CrossRefGoogle Scholar
  40. Docherty K. (1997) Gene therapy for diabetes mellitus. Clin Sci 92:321–330PubMedGoogle Scholar
  41. Dube I.D., Cournoyer D., (1995) Gene therapy: here to stay. Can Med Assoc J 152:1605–1613Google Scholar
  42. Dunbar C., Kohn D., Karlsson S. et al. (1996) Retroviral mediated transfer of the cDNA for human glucocerebro-sidase into hematopoietie stern cells of patients with Gaucher disease. A phase I study. Hum Gene Ther 7:231–253PubMedCrossRefGoogle Scholar
  43. During M. (1996a) Gene therapy chronology. Science 273:416–417PubMedCrossRefGoogle Scholar
  44. During M.J. (1996b) Gene trial in New Zealand. Lancet 348:618PubMedCrossRefGoogle Scholar
  45. Ekhterae D., Stanley J.C. (1995) Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. J Vasc Surg 21:953–962PubMedCrossRefGoogle Scholar
  46. Engel B.C., Laws H.J., Buttlies B., Kahn T., Gobel U., Burdach S.E.G. (1998) Induction of a CD3+/CD56+ lymphocyte population following gene therapy with transgenic IL-2 secreting fibroblasts in a child with peripheral neuroecto-dermal malignancy. Med Pediatr Oncol 31:56–60CrossRefGoogle Scholar
  47. Essex M., Matsuda Z., Yu X., Lee T.H. (1995) Gene therapy against retroviral diseases. Leukemia 9:71–74Google Scholar
  48. European Working Group of Gene Therapy E (1996) Newsletter No. i5Google Scholar
  49. Evans C.H., Mankin H.J., Ferguson A.B. Jr et al. (1996) Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritie cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther 7:1261–1306PubMedCrossRefGoogle Scholar
  50. Feldman L.J., Isner J.M. (1995) Gene therapy for the vulnerable plaque. J Am Coll Cardiol 26:826–835PubMedCrossRefGoogle Scholar
  51. Fenton R.T., Sznol M., Luster D.G., Taub D.D., Longo D.L. (1995) A phase I trial of B7-transfected or parentallethally irradiated allogeneie melanoma cell lines to induce cellmediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. Hum Gene Ther 6:87–106PubMedCrossRefGoogle Scholar
  52. Flotte T.R., Afione S.A., Zeitlin P.L. (1994) Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 11:517–521PubMedGoogle Scholar
  53. Flotte T.R., Conrad C., Reynolds T.Z. (1995) Preclinical evaluation of AAV vectors expressing the human CFTR cDNA (abstract). J Cell Biochem [Suppl 21A] 364:C366–112Google Scholar
  54. Flotte T.R., Carter B., Conrad C. et al. (1996) A phase 1 study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gen Ther 7:1145–1159CrossRefGoogle Scholar
  55. Flügel R.M. (1991) Spumaviruses: a group of complex retroviruses. J Acquir Immune Defic Syndr Hum Retrovirol 4:739–750Google Scholar
  56. Freeman T.B. (1997) From transplants to gene therapy for Parkinsons disease. Exp Neurol 144:47–50PubMedCrossRefGoogle Scholar
  57. Freeman S.M., McCune M.C., Robinson E. (1992) Treatment of ovarian cancer using HSV-TK gene-modified vaccine. Hum Gene Ther 3:342Google Scholar
  58. Freese A., Stern M., Kaplitt M.G. et al. (1996) Prospects for gene therapy in Parkinsons disease. Mov Disord 11:469–488PubMedCrossRefGoogle Scholar
  59. Friedmann T. (1996) Human gene therapy-an immature genie, but certainly out of the bottle. Nat Med 2:144–147PubMedCrossRefGoogle Scholar
  60. Fujiwara T., Grimm E.A., Roth J.A. (1994) Gene therapeutics and gene therapy for cancer. Curr Opin Oncol 6:96–105PubMedCrossRefGoogle Scholar
  61. Gahery-Segard H., Molinier-Frenkel V., Le Boulaire C. et al. (1997) Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J Clin Invest 100:2218–2226PubMedCrossRefGoogle Scholar
  62. Galpin J.E., Casciato D.A., Richards S.B. (1994) A phase I clinical trial to evaluate the safety and biologieal activity of HIV-IT (TAF) (HIV-1IIIBenv-transduced, autologous fibroblasts) in asymptomatie HIV-1 infected subjects. Hum Gene Ther 5:997–1017PubMedCrossRefGoogle Scholar
  63. Gßnsbacher B., Notzer R., Houghton A. et al. (1992) A pilot study of immunization with interleukin-2 secreting allogenic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther 3:691–703CrossRefGoogle Scholar
  64. Gßnsbacher B., Rosenthai F.M., Zier K. (1993) Retroviral vector-mediated cytokine-gene transfer into tumor cells. Cancer Invest 11:345–354CrossRefGoogle Scholar
  65. Gill D.R., Southern K.W., Mofford K.A. et al. (1997) A placebo controlled study of liposome mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 4:199–209PubMedCrossRefGoogle Scholar
  66. Ginsberg H.S. (ed) (1984) The adenoviruses. Plenum Press, New YorkGoogle Scholar
  67. Greene W.C. (1991) The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 324:308–317PubMedCrossRefGoogle Scholar
  68. Grossman M., Raper S.E., Kozarsky K. et al. (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6:335–341PubMedCrossRefGoogle Scholar
  69. Grossman M., Rader D.J., Muller D.W. et al. (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1:1148–1154PubMedCrossRefGoogle Scholar
  70. Günzburg W.H., Salmons B. (1992) Factors controlling the expression of mouse mammary tumour virus. Biochem J 283:625–632PubMedGoogle Scholar
  71. Günzburg W.H., Salmons B. (1995) Virus vector design in gene therapy. Mol Med Today 1:410–417PubMedCrossRefGoogle Scholar
  72. Habib N.A., Ding S.F., El-Masry R. et al. (1996) Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev 20:103–107PubMedGoogle Scholar
  73. Halbert C.L., Alexander I.E., Wolgamot G.M., Miller H.D. (1995) Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. Virology 69:1473–1479Google Scholar
  74. Halpern M.D., Pisetsky D.S. (1995) In vitro inhibition of murine IFN gamma production by phosporothioate deoxyguanosine oligomers. Immunopharmacology 29:47–52PubMedCrossRefGoogle Scholar
  75. Harris J.D., Lemoine N.R. (1996) Strategies for targeted gene therapy. Trends Genet 12:400–405 Harrison’s principles of internal medicine, 13th edn (1994) McGraw-Hill, New YorkGoogle Scholar
  76. Hatzoglou M., Lamers W., Bosch F., Wynshaw B.A., Clapp D.W., Hanson R.W. (1990) Hepatic gene transfer in animals using retroviruses containing the promoter from the gene for phosphoenolpyruvate carboxykinase. J Biol Chem 265:17285–17293PubMedGoogle Scholar
  77. Haubrich R., McCutchan J.A., Holdredge R., Heiner L., Merritt J., Merchant B. (1995) An open label, phase I/II clinical trial to evaluate the safety and biological activity of HIV-1-IT (V) (HIV-1(IIIB)(env/rev) retroviral vector) in HIV-1-infected subjects. Hum Gene Ther 6:941–955PubMedCrossRefGoogle Scholar
  78. Hay J.G., McElvaney N.G., Herena J., Crystal R.G. (1995) Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of anormal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 6: 1487–1496PubMedCrossRefGoogle Scholar
  79. Herrman J.P.R., Hermans W.R., Vos J., Serruys P.W. (1993) Pharmacological approaches to the prevention of restenosis following angioplasty. The search for the Holy Gram (Part I). Drugs 46:18–52PubMedCrossRefGoogle Scholar
  80. Herweijer H., Latendresse J.S., Williams P. et al. (1995) A plasmid-based self-amplifying sindbis virus vector. Hum Gene Ther 6:1161–1167PubMedCrossRefGoogle Scholar
  81. Hesdorffer C., Antman K., Bank A., Fetell M., Mears G., Begg M. (1994) Clinical protocol: human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 5:1151–1160PubMedCrossRefGoogle Scholar
  82. Hesdorffer C., Ayello J., Ward M. et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDRI gene as marrow chemoprotection in patients undergoing highdose chemotherapy and autologous stem-cell transplantation. J Clin Oncol. 16: 165–172PubMedGoogle Scholar
  83. Hijiya N., Zhang J., Ratajczak M.Z. et al. (1994) Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl Acad Sci USA 91:4499–4503Google Scholar
  84. Hoogerbrugge P.M., von Beusechem V.W., Kaptein L.C., Einerhand M.P., Valerio D. (1995) Gene therapy for adenosine deaminase deficiency. Br Med Bull 51:72–81PubMedGoogle Scholar
  85. Hoogerbrugge P.M., Van Beusechem V.W., Fischer A. et al. (1996) Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3: 179–183PubMedGoogle Scholar
  86. Horowitz M.S. (1990) Adenoviridaee and their replication. In: Fields B.N., Knipe D.M. (eds) Virology. Raven Press, New York, pp 1679–1740Google Scholar
  87. Hsieh S.Y., Taylor J. (1992) Delta virus as a vector for the delivery of biologically-aetive RNAs: possibly a ribozyme speeifie for chronic hepatitis B virus infection. Adv Exp Med Biol 312:125–128PubMedCrossRefGoogle Scholar
  88. Huebner R.J., Rowe W.P., Ward T.G. et al. (1954) Adenoidal-pharyngeal-conjunctival agents. N Engl J Med 251:1077–1086PubMedCrossRefGoogle Scholar
  89. Huehns T.Y., Krausz E., Mrochen S. et al. (1999) Neointimal growth ean be influenced by local adventitial gene manipulation via a needle injeetion catheter. Atherosclerosis 144:135–150PubMedCrossRefGoogle Scholar
  90. Hui K.M., Ang P.T., Huang L., Tay S.K. (1997) Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Ther 4:783–790PubMedCrossRefGoogle Scholar
  91. Isner J.M. (1998) Arterial gene transfer of naked DNA for therapeutic angiogenesis: early clinical results. Adv Drug Deliv Rev 30:185–197PubMedCrossRefGoogle Scholar
  92. Isner J.M., Walsh K., Symes J. et al. (1995) Arterial gene therapy for therapeutic angiogenesis in patients with peripheral artery disease. Cireulation 91:2687–2692CrossRefGoogle Scholar
  93. Isner J.M., Pieczek A., Schainfeld R. et al. (I996a) Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF165 in patients with isehaemic limb. Lancet 348:370–374Google Scholar
  94. Isner J.M., Walsh K., Symes J. et al. (1996b) Clinical protocol: arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 7:959–988PubMedCrossRefGoogle Scholar
  95. Isner J.M., Walsh K., Rosenfield K. et al. (1996e) Arterial gene therapy for restenosis. Hum Gene Ther 7:989–1011PubMedCrossRefGoogle Scholar
  96. Izquierdo M., Cortes M.L., Martin V. et al. (1997) Gene therapy in brain tumours: implications of the size of glioblastoma on its curability. Acta Neurochir Suppl (Wien) 68:111–117Google Scholar
  97. Jantscheff P., Bongartz G., Dietrich P.Y. et al. (1997) Phase I study of cytokine-transfected xenogeneic cells (Vero-IL2) in patients with metastatic solid tumors. J Mol Med 75:B31Google Scholar
  98. Juengst E.T. (1995) Prevention and the goals of genetic medicine. Hum Gene Ther 6:1595–1605PubMedCrossRefGoogle Scholar
  99. Kalle C. von, Kiem H.P., Goehle S. et al. (1994) Increased gene transfer into human hematopoietic progenitor cells by extended in vitro exposure to a pseudotyped retroviral vector. Blood 84:2890–2897Google Scholar
  100. Kircheis R., Kichler A., Wallner G. et al. (1997) Coupling of cell binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 4:409–418PubMedCrossRefGoogle Scholar
  101. Knowles M.R., Hohneker K.W., Zhou Z. et al. (1995) A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823–831PubMedCrossRefGoogle Scholar
  102. Kohn D., Weinberg K.I., Parkman P. et al. (1993) Gene therapy for neonates with ADA-deficient SCID by retroviralmediated transfer of the human ADA cDNA into umbilical cord CD34+ cells. Blood [Suppl 1] 82:315aGoogle Scholar
  103. Kohn D.B., Weinberg K.I., Nolta J.A. et al. (1995) Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med 1:1017–1023PubMedCrossRefGoogle Scholar
  104. Kohn D.B., Hershfield M.S., Corbonaro D. et al. (1998) T lymphocytes with anormal ADA gene accumulate after transplantation of transduced autologous umbilieal cord blood CD34+ cells in ADA-defieient SCID neonates. Nat Med 4:775–780PubMedCrossRefGoogle Scholar
  105. Kutryk M.J.B., Groot M.R. de, Brand M. van den et al. (1997) Feasibility of the local delivery of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: acute results of the Thoraxeentre „ITALICS” trial. 14th Congress of the European Society of Cardiology, Stockholm, p 2918Google Scholar
  106. Laitinen M., Pakkanen T., Donetti E. et al. (1997) Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum Gene Ther 8:1645–1650PubMedCrossRefGoogle Scholar
  107. Lang Z.H., Feingold J.M. (1996) An autonomously replicating eukaryotic expression vector with a tetracycline responsive promoter. Gene 168:169–171PubMedCrossRefGoogle Scholar
  108. Ledley F.D. (1995) Nonviral gene therapy: the promise of genes as pharmaceutieal products. Hum Gene Ther 6:1129–1144PubMedCrossRefGoogle Scholar
  109. Lee S.W., Kahn M.L., Dichek D.A. (1992) Expression of an anchored urokinase in the apieal endothelial cell membrane. Preservation of enzymatie activity and enhancement of cell surface plasminogen activation. J Biol Chem 267:13020–13027PubMedGoogle Scholar
  110. Lee S.W., Kahn M.L., Dichek D.A. (1993) Control of clot lysis by gene transfer. Trends Cardiovasc Med 3:61–66PubMedCrossRefGoogle Scholar
  111. Lewis P.F., Emerman M. (1994) Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510–516PubMedGoogle Scholar
  112. Link C.J., Moorman D., Seregina T., Levy J.P., Schabold K.J. (1995) A phase I trial of in vivo gene therapy with the Herpes simplex thymidine kinase ganciclovir system for the treatment of refractory or recurrent ovarian cancer. Cancer Gene Ther 2:230–231Google Scholar
  113. Liu J.M. (1998) Gene transfer for the eventual treatment of Fanconi’s anemia. Semin Hematol 35: 168–179PubMedGoogle Scholar
  114. Liu J.M., Young N.S., Walsh C.E. et al. (1997) Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietie progenitors of group C patients. Hum Gene Ther 8:1715–1730PubMedCrossRefGoogle Scholar
  115. Losordo D.W., Vale P.R., Symes I.F. et al. (1998) Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98:2800–2804PubMedCrossRefGoogle Scholar
  116. Lotze M.T., Rubin I.T. (1995) Report of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH)Google Scholar
  117. Lotze M.T., Rubin J.T., Carty S. et al. (1994) Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Hum Gene Ther 5:41–55PubMedCrossRefGoogle Scholar
  118. Lu D.R., Zhou J.M., Zheng B. et al. (1993) Stage I clinical trial of gene therapy for hemophilia B. Sci China B 36:1342–1351PubMedGoogle Scholar
  119. MacGregor R.R., Boyer J.D., Ugen K.E. et al. (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92–100PubMedCrossRefGoogle Scholar
  120. Mackensen A., Veelken H., Lahn M. et al. (1997) Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts. J Mol Med 75:290–296PubMedCrossRefGoogle Scholar
  121. Malech H.L., Maples P.B., Whiting-Theobald N. et al. (1997) Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci USA 94:12133–12138Google Scholar
  122. Malkin D., Portwine C. (1994) The geneties of childhood cancer. Eur J Cancer 30a:1942–1946PubMedCrossRefGoogle Scholar
  123. Marcel T., Grausz J.D. (1996) TCM Worldwide Gene Therapy Enrollment Report. TMC DevelopmentGoogle Scholar
  124. Marshali E. (1996) New Zealand’s leap into gene therapy. Science 271: 1489–1490CrossRefGoogle Scholar
  125. Matrangeli A., Harvey B.G., Yao J. (1994) Effieient in vivo adenovirus-mediated gene transfer to the airway epithelium of animals immunized with differnt adenovirus serotypes. North Ameriean Cystic Fibrosis Meeting. Late Breaking Sciene S5–6Google Scholar
  126. McElvaney N.G., Crystal R.G. (1995) IL-6 release and airway administration of human CFTR cDNA adenovirus vector [2]. Nat Med 1:182–184PubMedCrossRefGoogle Scholar
  127. Mebatsion T., Schnell M.J., Cox I.H., Finke S., Conzelmann K.K. (1996) Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci USA 93:7310–7314Google Scholar
  128. Merrouche Y., Negrier S., Bain C. et al. (1995) Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J Clin Oncol 13:410–418PubMedGoogle Scholar
  129. Millauer B., Shawver L.K., Plate K.H., Risau W., Ullrieh A. (1994) Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576–579PubMedCrossRefGoogle Scholar
  130. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., Martuza R.L. (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938–943PubMedCrossRefGoogle Scholar
  131. Motulski A., Orkin S.C. (1995) Report and recommendation of the panel to assess the NIH investment in research on gene therapy. Website: http://www.nih.gov/news/panelrep.htmlGoogle Scholar
  132. Mukherjee S., Haenel T., Epton M. (1997) Intralesional vaccinia virus-interleukin-2 (VV-IL-2) gene therapy in malignant mesothelioma (MM). Lung Cancer [Suppl 1] 18:236CrossRefGoogle Scholar
  133. Nabel E.G., Gordon D., Yang Z.Y. et al. (1992a) Gene transfer in vivo with DNA-liposome complexes: lack of autoimmunity and gonadal localization. Hum Gene Ther 3:649–656PubMedCrossRefGoogle Scholar
  134. Nabel G.J., Chang A., Nabel E.G. et al. (1992b) Immunotherapy of malignancy by in vivo gene transfer into tumors. Hum Gene Ther 3:399–410CrossRefGoogle Scholar
  135. Nabel G.I., Nabel E.G., Yang Z.Y. et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologie activity, and lack of toxieity in humans. Proc Natl Acad Sci USA 90:11307–11311Google Scholar
  136. Nabel E.G., Yang Z., Muller D. et al. (1994a) Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanorna. Hum Gene Ther 5:1089–1094PubMedCrossRefGoogle Scholar
  137. Nabel G.J., Chang A.E., Nabel E.G. et al. (1994b) Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 5:57–77PubMedCrossRefGoogle Scholar
  138. Nabel G.I., Yang Z.Y., Nabel E.G. et al. (1995) Direct gene transfer for treatment of human cancer. Ann N Y Acad Sci 772:227–231PubMedCrossRefGoogle Scholar
  139. Niemann T.H., Trigg M.E., Winick N., Penick G.D. (1993) Disseminated adenoviral infection presenting as acute pancreatitis. Hum Pathol 24:1145–1148PubMedCrossRefGoogle Scholar
  140. Nikol S., Huehns T.Y., Krausz E. et al. (1999) Needle injection catheter delivery of the gene for an antibacterial agent inhibits neointimal formation. Gene Ther 6:737–748PubMedCrossRefGoogle Scholar
  141. Noguiez Heilin P., Meur M.R., Salzmann J.L., Klatzmann D. (1996) Plasmoviruses: nonviral/viral vectors for gene therapy. Proc Natl Acad Sci USA 93:4175–4180Google Scholar
  142. Oldfield E.H., Ram Z., Chiang Y., Blaese R.M. (1995) Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum Gene Ther 6:55–85PubMedCrossRefGoogle Scholar
  143. Onodera M., Ariga T., Kawamura N. et al. (1998) Successful peripheral T-Iymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91:30–36PubMedGoogle Scholar
  144. O’Shaughnessy J.A., Cowan K.H., Nienhuis A.W. et al. (1994) Clinical protocol: retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stern cells during autologous transplantation after intensive chemotherapy for metastatie breast cancer. Hum Gen Ther 5:891–911CrossRefGoogle Scholar
  145. Parmiani G., Arienti F., Sulesuso J. et al. (1996) Tissue Culture Society Congress, Brno, April 21-24, 1996. Cytokine based gene therapy of human tumors. An overview. Folia Biol (Prah a) 42:305–309Google Scholar
  146. Podsakoff G., Wong Jr K.K., Chatterjee S. (1994) Effieient gene transfer into nondividing ceils by adeno-assoeiated virusbased vectores. J Virol 68:5656–5666PubMedGoogle Scholar
  147. Porteous D.J., Dorin J.R., McLachlan G. et al. (1997) Evidence for safety and efficacy of DOTAP cationie liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystie fibrosis. Gene Ther 4:210–218PubMedCrossRefGoogle Scholar
  148. Qiu X., Lu D., Zhou J. et a1. (1996) Implantation of autologous skin fibroblast genetieally modified to secrete clotting factor IX partially corrects the hemorrhagie tendeneies in two hemophilia B patients. Chin Med J (Engl) 109:832–839Google Scholar
  149. Rakhmilevich A.L., Turner J., Ford M.J. et al. (1996) Gene gun mediated skin transfeetion with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 93:6291–6296Google Scholar
  150. Ram Z., Culver K., Oshiro E. (1995) Summary of results and conclusions of the gene therapy of malignant brain tumors: Clinical study. J Neurosurg 82:343AGoogle Scholar
  151. Recombinant DNA Advisory Committee (RAC) der NIH (1995) Data management seientific report and status report, Stand 2.6.1995Google Scholar
  152. Recombinant DNA Advisory Committee (RAC) der NIH (1996) Human gene transfer protocols, Stand 26.4.1996Google Scholar
  153. Redmond D.E. (1997) Gene therapy approaches to Parkinsons disease: preClinical to clinical trials, or what steps to take to get there from here. Exp Neurol 144:160–167PubMedCrossRefGoogle Scholar
  154. Riddell S.R., Elliott M., Lewinsohn D.A. et al. (1996) T-cell mediated rejection of gene-modified HlV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2:216–223PubMedCrossRefGoogle Scholar
  155. Rigg R.J., Chen J., Dando J.S., Forestell S.P., Plavec I., Bohnlein E. (1996) A novel human amphotropie packaging ceil line: high titer, complement resistance, and improved safety. Virology 218:290–295PubMedCrossRefGoogle Scholar
  156. Rosenberg S.A. (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199PubMedGoogle Scholar
  157. Rosenberg Z.F., Fauei A.S. (1990) Immunopathogenic mechanisms of HlV infection: cytokine induction of HlV expression. Immunol Today 11:176PubMedCrossRefGoogle Scholar
  158. Rosenberg S.A., Aebersold P., Cornetta K. et a1. (1990) Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578PubMedCrossRefGoogle Scholar
  159. Rosenberg S.A., Yannelli J.R., Yang J.C. et al. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159–1166PubMedCrossRefGoogle Scholar
  160. Rossi J.J. (1995) Therapeutic antisense and ribozymes. Br Med Bull 51:217–225PubMedGoogle Scholar
  161. Roth J.A. (1996) Modification of tumor suppressor gene expression in non small ceillung cancer (Nsclc) with a retroviral vector expressing wildtype (normal) p53. Hum Gene Ther 7:861–874PubMedCrossRefGoogle Scholar
  162. Roth J.A., Nguyen D., Lawrence D.D. et al. (1996) Retrovirus mediated wild type p53 gene transfer to tumors of patients with lung cancer. Nat Med 2:985–991PubMedCrossRefGoogle Scholar
  163. Roth J.A. (1997) 33rd American Soeiety of Clinical Oncology (ASCO) Annual Meeting (Abstract)Google Scholar
  164. Roth J.A., Cristiano R.J. (1997) Gene therapy for cancer: what have we done and where are we going. J Natl Cancer Inst 89:21–39PubMedCrossRefGoogle Scholar
  165. Rubin J., Charboneau J.W., Reading C., Kovach J.S. (1994) Phase I study of immunotherapy of hepatie metastases of colorectal careinoma by direct gene transfer. Hum Gene Ther 5:1385–1399PubMedCrossRefGoogle Scholar
  166. Sakiyama Y. (1996a) Clinical study of gene therapy for ADA deficiency. Aerugi 45:621–626Google Scholar
  167. Sakiyama Y. (1996 b) Gene therapy for adenosine deaminase deficiency. Hokkaido Igaku Zasshi 71:27–32PubMedGoogle Scholar
  168. Samulski R.J. (1993) Adeno-assoeiated virus: integration at a specific chromosomal locus. Curr Opin Genet Dev 3:74–80PubMedCrossRefGoogle Scholar
  169. Scanlon K.J., Ohta Y., Ishida H. et a1. (1995) Oligonucleotide-mediated modulation of mammalian gene expression. FASEB J 9:1288–1296PubMedGoogle Scholar
  170. Schadendorf D., Czarnetzki B.M., Wittig B. (1995) Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatie melanoma. J Mol Med 73:473–477PubMedCrossRefGoogle Scholar
  171. Schweigerer L. (1995) Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73:497–508PubMedCrossRefGoogle Scholar
  172. Sekhon H.S., Larson J.E. (1995) In utero gene transfer into the pulmonary epithelium. Nat Med 1:1201–1203PubMedCrossRefGoogle Scholar
  173. Simons M., Edelman E.R., DeKeyser J.L., Langer R., Rosenberg R.D. (1992) Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 359:67–70PubMedCrossRefGoogle Scholar
  174. Sobol R.E., Fakhrai H., Shawler D. et a1. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164–167PubMedGoogle Scholar
  175. Son K., Huang L. (1994) Exposure of human ovarian careinoma to eisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer. Proc Natl Acad Sci USA 91:12669–12672Google Scholar
  176. Spiegel M., Bitzer M., Schenk A. et al. (1998) Pseudotype formation of Moloney murine leukemia virus with Sendai virus glycoprotein F. J Virol 72:5296–5302PubMedGoogle Scholar
  177. Stein C.A., Cheng Y.C. (1993) Antisense oligonucleotides as therapeutic agents-is the bullet really magieal? Science 261:1004–1012PubMedCrossRefGoogle Scholar
  178. Sterman D.H., Treat J., Litzky L.A. et al. (1998a) Adenovirusmediated herpes simplex virus thymidine kinase/ganeiclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9: 1083–1092PubMedCrossRefGoogle Scholar
  179. Sterman D.H., Kaiser L.R., Albelda S.M. (1998b) Gene therapy for malignant pleural mesothelioma. Gene Ther 12:553–568Google Scholar
  180. Stopeck A.T., Hersh E.M., Akporiaye E.T. et al. (1997) Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15:341–349PubMedGoogle Scholar
  181. Sun Y., Jurgovsky K., Moller P. et al. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 5:481–490PubMedCrossRefGoogle Scholar
  182. Tait D.L., Obermiller P.S., Redlin-Frazier S. et al. (1997) A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer. Clin Cancer Res 3:1959–1968PubMedGoogle Scholar
  183. Tan Y., Xu M., Wang W. et al. (1996) IL-2 gene therapy of advanced lung cancer patients. Anticancer Res 16:1993–1998PubMedGoogle Scholar
  184. Tjuvajev J.G., Stockhammer G., Desai R. et al. (1995) Imaging the expression of transfected genes in vivo. Cancer Res 55:6126–6132PubMedGoogle Scholar
  185. Tolstoshev P. (1993) Gene therapy, concepts, current trials and future directions. Annu Rev Pharmacol Toxicol 33:573–596PubMedCrossRefGoogle Scholar
  186. Touchette N. (1996) Gene therapy-not ready for prime time. Nat Med 2:7–8CrossRefGoogle Scholar
  187. Tripathy S.K., Black H.B., Goldwasser E., Leiden J.M. (1996) Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replicationdefective adenovirus vectors. Nat Med 2:545–550PubMedCrossRefGoogle Scholar
  188. Tsang K.Y., Zaremba S., Nieroda C.A., Zhu M.Z., Hamilton J.M., Schlom J. (1995) Generation of human cytotoxic T-cell specific for human carcinoembryonic antigen (CEA) epitopes from patients immunized with recombinant vaccinia-CEA (rV-CEA) vaccine. J Natl Cancer lust 87:982–990CrossRefGoogle Scholar
  189. Tursz T., Cesne A.L., Baldeyrou P. et al. (1996) Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Natl Cancer lust 88:1857–1863CrossRefGoogle Scholar
  190. Ueba T., Nosaka T., Takahashi J.A. et al. (1994) Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and heptacellular carcinoma cells. Proc Natl Acad Sci USA 91:9009–9013Google Scholar
  191. Van Meir E.G., Polverini P.J., Chanzin V.R., Huang H-J., Tribolet N. de, Cavenee W.K. (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8: 171–176PubMedCrossRefGoogle Scholar
  192. Veelken H., Mackensen A., Lahn M. et al. (1997) A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer 70:269–277PubMedCrossRefGoogle Scholar
  193. Waddill W., Wright W., Unger E., et al. (1997) Human gene therapy for melanoma: Ct guided interstitial injection. AJR Am J Roentgenol 169:63–67PubMedGoogle Scholar
  194. Wagner E., Zenke M., Cotten M., Beug H., Birnstiel M.L. (1990) Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc Natl Acad Sci USA 87:3410–3414Google Scholar
  195. Walker R., Bechtel C.M., Natarajan V. et al. (1995) Adoptive transfer of genetically modified, HIV-specific, syngeneic cytotoxic T lymphocytes (CTL) in HIV discordant identical twins. 3rd Conference on Retroviruses and Opportunistic Infections. Washington, DC, Abstract 404Google Scholar
  196. Weber F., Bojar H., Priesack H.B. et al. (1997) Gene therapy of glioblastoma-one year clinical experience with ten patients (abstract). J Mol Med [Suppl 5] 75:B40Google Scholar
  197. Welsh M.J., Zabner J., Graham S.M., Smith A.E., Moscicki R.Google Scholar
  198. Wadsworth S. (1995) Adenovirus-mediated gene transfer for cystic fibrosis: Part A. Safety of dose and repeat administration in the nasal epithelium. Part B. Clinical efficacy in the maxillary sinus. Hum Gene Ther 6:205–218PubMedCrossRefGoogle Scholar
  199. Wiley Stand 1.12.1998, Wiedergabe mit Erlaubnis von Wiley J. Gene Medicine. Website: http://www.wiley.co.uk/genmed.Google Scholar
  200. Wills K.N., Maneval D.C., Menzel P. et al. (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079–1088PubMedCrossRefGoogle Scholar
  201. Wilson J.M. (1995) Report of the Recombinant DNA Advisory Committee (RAC) of the National Institutes of Health (NIH)Google Scholar
  202. Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. (1996) Expression of a protective gene prolongs survival of T cells in human immunodefieiency virus-infected patients. Proc Natl Acad Sci USA 93:2889–2894Google Scholar
  203. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. (1994a) Cellular immunity to viral antigens limits E 1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–4411Google Scholar
  204. Yang Y., Nunes F.A., Berencsi K., Gonczol E., Engelhardt J.F., Wilson J.M. (1994 b) Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362–369PubMedCrossRefGoogle Scholar
  205. Woffendin C., Ranga U., Yang Z., Xu L., Nabel G.J. (1996) Expression of a protective gene prolongs survival of T cells in human immunodefieiency virus-infected patients. Proc Natl Acad Sci USA 93:2889–2894Google Scholar
  206. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. (1994a) Cellular immunity to viral antigens limits E 1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–4411Google Scholar
  207. Yang Y., Nunes F.A., Berencsi K., Gonczol E., Engelhardt J.F., Wilson J.M. (1994 b) Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7:362–369PubMedCrossRefGoogle Scholar
  208. Zabner J., Couture L.A., Gregory R.J., Graham S.M., Smith A.E., Welsh M.J. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75:207–216PubMedCrossRefGoogle Scholar
  209. Zabner J., Fasbender A.J., Moninger T., Poellinger K.A., Welsh M.J. (1995) Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 270:18997–19007PubMedCrossRefGoogle Scholar
  210. Zabner J., Ramsey B.W., Meeker D.P. et al. (1996) Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin luvest 97:1504–1511CrossRefGoogle Scholar
  211. Ziegner U.H., Peters G., Jolly D.J. et al. (1995) Cytotoxic T-Iymphocyte induction in asymptomatic HIV-1-infected patients immunized with retrovector-transduced autologous fibroblasts expressing HIV-HIIB Env/Rev proteins. AIDS 9:43–50PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2000

Authors and Affiliations

  • Sigrid Nikol

There are no affiliations available

Personalised recommendations